Please try another search
For the nine months ended 31 December 2014, Ranbaxy Laboratories Limited revenues decreased 23% to RS82.95B. Net loss decreased 27% to RS7.38B. Revenues reflect Other operating revenues decrease of 40% to RS1.18B. Lower net loss reflects Other expenses decrease of 37% to RS24.24B (expense), Employee benefits expenses decrease of 23% to RS15.97B (expense), Exceptional-Loss/Gian on forgn currency decrease of 99% to RS55.4M (expense).
Period Ending: | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 |
---|---|---|---|---|
Total Revenue | 26188.46 | 32604.91 | 24160.29 | 24668.21 |
Gross Profit | 15719.92 | 22534.41 | 15456.61 | 15418.93 |
Operating Income | 1487.76 | 7770.45 | -1192.65 | -348.56 |
Net Income | -10297.27 | 4777.56 | -1859.28 | -736.54 |
Period Ending: | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 |
---|---|---|---|---|
Total Assets | 140587.56 | 139901.18 | ||
Total Liabilities | 104137.48 | 106875.56 | ||
Total Equity | 36450.08 | 33025.62 |
Period Ending: | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review